Big pharma, Deals, Partnering, Pharma

Johnson & Johnson gives a settlement of $2.2 billion for various misdemeanor

Posted on 06 November 2013

Tags: , , , ,

Johnson & Johnson agrees to pay a settlement of $2.2 billion for a dispute of over 8 years.

Johnson & Johnson and its subsidiaries, Janssen Pharmaceuticals and Scion have finalized previously disclosed settlement agreements with the U.S. Department of Justice (DOJ) and 45 states resolving federal investigations and state Medicaid claims related to past promotional practices of RISPERDAL from 1999 through 2005, and other matters.

The resolution includes total settlement amounts of approximately $2 billion to the federal government and state Medicaid programs, an amount previously accrued.

Janssen will plead guilty to a single misdemeanor violation of the Food, Drug and Cosmetic Act for past promotional practices of RISPERDAL.

The agreement also resolves allegations related to the sales and marketing of INVEGA, NATRECOR by Scios Inc., and allegations related to Janssen's interactions with Omnicare.

Janssen will pay $400 million and plead guilty to a one-count misdemeanor misbranding charge.

Janssen and Scios will pay approximately $1.6 billion to settle three pending civil False Claims Act cases in federal district courts related to RISPERDAL and INVEGA, NATRECOR, and Omnicare.

Read the full article in Wall Steert Journal

 

Related

Report: Inflammatory Bowel Disease Partnering

Report: Partnering Deals and Alliances with Johnson & Johnson / Janssen

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new1gif
e80banner300x150animgif
a1banner300x150animgif